SC
TAK icon

Stephens Consulting’s Takeda Pharmaceutical TAK Stock Holding History

Stephens Consulting’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-450
Closed -$6.96K – 1069
2025
Q2 		$6.96K Buy
+450
New +$6.65K ﹤0.01% 365

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Stephens Consulting's TAK Position: Q3 2025 in Review

Stephens Consulting sold out of Takeda Pharmaceutical (TAK) in Q3 2025, closing a stake of 450 shares — an estimated $6.96K sold.

Stephens Consulting first reported a position in TAK in Q2 2025 and held it in 1 quarter. The position peaked at $6.96K in Q2 2025. 329 funds tracked by Wall St. Rank hold TAK as of Q3 2025.

  • Stephens Consulting reported no remaining Takeda Pharmaceutical position as of Q3 2025 after selling out during the quarter.
  • Stephens Consulting sold 450 Takeda Pharmaceutical shares in Q3 2025, an estimated $6.96K.
  • Stephens Consulting first reported a position in Takeda Pharmaceutical in Q2 2025 and held it in 1 quarter.
  • Stephens Consulting's Takeda Pharmaceutical position peaked at $6.96K in Q2 2025.
  • 329 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q3 2025.

Based on Stephens Consulting's 13F filing for Q3 2025, filed 15 Oct 2025.